Open access
Open access
Powered by Google Translator Translator

Chest Medicine (all articles)

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

3 Oct, 2021 | 23:02h | UTC

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Commentaries:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

 

Commentaries on Twitter

(thread – click for more)

 

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

3 Oct, 2021 | 22:59h | UTC

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ

Original Guidance: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Related:

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Will the pandemic fade into an ordinary disease like the flu? The world is watching Denmark for clues.

3 Oct, 2021 | 22:58h | UTC

Will the pandemic fade into an ordinary disease like the flu? The world is watching Denmark for clues – Science

 

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

3 Oct, 2021 | 22:49h | UTC

Covid-19 vaccination: evidence of waning immunity is overstated – The BMJ

Related:

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

3 Oct, 2021 | 22:33h | UTC

Summary: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness? – Cochrane Library

Original article: Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE – Cochrane Library

 

International registry shows mortality after ECMO for patients with COVID-19 worsened during 2020.

1 Oct, 2021 | 10:43h | UTC

Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry – The Lancet

Commentaries:

ECMO in COVID-19: do not blame the tool – The Lancet

ECMO life support offers sickest COVID-19 patients a chance to survive, but a slimmer one than once thought – Michigan Medicine – University of Michigan

 

Commentary on Twitter (thread – click for more)

 

Transition to endemicity: Understanding COVID-19.

1 Oct, 2021 | 10:30h | UTC

Transition to endemicity: Understanding COVID-19 – Cell

Related:

COVID will likely shift from pandemic to endemic — but what does that mean?

Perspective | How Endemic COVID Becomes a Manageable Risk – “Businesses and schools must adapt, because the dual threat from the coronavirus and the flu will be too severe”.

 

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

1 Oct, 2021 | 10:35h | UTC

A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients – Frontiers in Pharmacology

Related: M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

 

Review: COVID-19 in older adults.

1 Oct, 2021 | 10:27h | UTC

COVID-19 in older adults – Cleveland Clinic Journal of Medicine

 

RCT: REGEN-COV antibody combination reduces hospitalizations in outpatients with Covid-19.

30 Sep, 2021 | 10:33h | UTC

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 – New England Journal of Medicine

 

[Press release – Not published yet] Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta.

30 Sep, 2021 | 10:30h | UTC

Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest – Clover Biopharmaceutical

Commentary: New Chinese vaccine could bolster global arsenal – Science

 

Randomized trial with over 30.000 patients showed AstraZeneca vaccine was safe and resulted in 74% efficacy against symptomatic SARS-CoV-2 infection.

30 Sep, 2021 | 10:32h | UTC

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine – New England Journal of Medicine

 

Commentaries on Twitter

 

Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom.

30 Sep, 2021 | 10:25h | UTC

News release: Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom – University of Oxford

Original study: Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 – PLOS Medicine

Commentaries:

Two studies tie long COVID-19 to severe initial illness – CIDRAP

Covid: 37% of people have symptoms six months after infection – The Guardian

Long Covid is a bigger problem than we thought – CNN

Expert reaction to study looking at incidence and co-occurrence of long COVID symptoms following COVID-19 infection and also after influenza – Science Media Centre

 

Supplement: Acute Respiratory Distress Syndrome.

30 Sep, 2021 | 10:03h | UTC

Homepage: Acute Respiratory Distress Syndrome – Critical Care Clinics

The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019

Toward Optimal Acute Respiratory Distress Syndrome Outcomes

Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury

COVID-19–Associated Acute Respiratory Distress Syndrome

Pathophysiology of the Acute Respiratory Distress Syndrome

Acute Kidney Injury and Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

Fluid Therapy and Acute Respiratory Distress Syndrome

Pharmacologic Treatments for Acute Respiratory Distress Syndrome

Long-Term Outcomes in Acute Respiratory Distress Syndrome

Related:

Position paper: Advancing precision medicine for acute respiratory distress syndrome.

Review: Personalized mechanical ventilation in acute respiratory distress syndrome.

Seminar | Acute respiratory distress syndrome.

M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies.

M-A: High versus low PEEP levels for mechanically ventilated adult patients with acute lung injury and ARDS

M-A: Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids

ARDS: Contemporary management and novel approaches during COVID-19

Systematic review: Evidence-based practices for acute respiratory failure and Acute Respiratory Distress Syndrome

Current and evolving standards of care for patients with acute respiratory distress syndrome (ARDS). Definition, ventilatory support, fluid management, use of corticosteroids, indications of prone positioning and ECMO, and more.

 

M-A: Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients.

29 Sep, 2021 | 10:24h | UTC

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis – Reviews in Medical Virology

 

Characterizing long COVID: a living systematic review.

29 Sep, 2021 | 10:29h | UTC

Characterising long COVID: a living systematic review – BMJ Global Health

Related:

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Commentary on Twitter

 

COVID-19 testing moves out of the clinic and into the home.

28 Sep, 2021 | 09:46h | UTC

COVID-19 Testing Moves Out of the Clinic and Into the Home – JAMA

 

Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.

28 Sep, 2021 | 09:51h | UTC

News release: COVID-19 has caused the biggest decrease in life expectancy since World War II – University of Oxford

Original study: Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries – International Journal of Epidemiology

Commentaries:

Life expectancy falls in 27 of 29 nations amid COVID-19 – CIDRAP

Covid has wiped out years of progress on life expectancy, finds study – The Guardian

Related:

Just how do deaths due to COVID-19 stack up?

Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.

Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.

Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.

COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

 

Commentary on Twitter

 

Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go.

28 Sep, 2021 | 09:45h | UTC

Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go – The Conversation

Related: [Preprint] Largest study of masks yet details their importance in fighting Covid-19.

 

Updated WHO Living Guideline: Therapeutics and COVID-19.

26 Sep, 2021 | 22:16h | UTC

Therapeutics and COVID-19: living guideline – World Health Organization

WHO Statement: On new recommendation for treatment of COVID-19 patients: WHO calls for equitable access to casirivimab and imdevimab for COVID-19

See also:

WHO recommends antibody treatment for COVID patients at high risk of hospital admission.

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis – The BMJ

Commentary: WHO adds new recommendation for COVID-19 monoclonal antibody combo – CIDRAP

 

Systematic Review: Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnea.

26 Sep, 2021 | 21:36h | UTC

Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea – Cochrane Library

Summary: Non-invasive positive airway pressure therapy to improve erectile dysfunction in men with obstructive sleep apnoea – Cochrane Library

 

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

24 Sep, 2021 | 10:13h | UTC

Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial – medRxiv

Related: COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

 

Commentary on Twitter

 

Systematic Review: Pulmonary rehabilitation for interstitial lung disease.

26 Sep, 2021 | 21:31h | UTC

Pulmonary rehabilitation for interstitial lung disease – Cochrane Library

Summary: Pulmonary rehabilitation for interstitial lung disease – Cochrane Library

 

No, vaccinated people are not ‘just as likely’ to spread the Coronavirus as unvaccinated people.

24 Sep, 2021 | 10:06h | UTC

No, Vaccinated People Are Not ‘Just as Likely’ to Spread the Coronavirus as Unvaccinated People – The Atlantic

 

Commentary on Twitter

 

WHO recommends antibody treatment for COVID patients at high risk of hospital admission.

24 Sep, 2021 | 10:11h | UTC

WHO recommends antibody treatment for COVID patients at high risk of hospital admission – British Medical Journal

Original article and infographic: A living WHO guideline on drugs for covid-19 – The BMJ

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.